RMD - Mergers and acquisitions

Noctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa

Expands ResMed's sleep management software solution, will help sleep labs and physicians more efficiently guide patients into and through diagnosis to long-term treatmentDiagnostic management platform is upstream of and complementary to ResMed's current post-testing AirView and Brightree offeringsSomnoware platform will remain an open platform to enable sleep labs, pulmonary function testing facilities, and physicians to view results from various testing solutions and help diagnosed patients get onto the treatment they need faster SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced the acquisition of privately held Somnoware, a U.S. leader in sleep a

Acquisition lays foundation to build ResMed's digital sleep medicine portfolio in Germanysomnio digital health application focused on improving sleep in patients with diagnosed insomnia, filling care gap and providing alternative to prevailing drug therapy mementor to be integrated into ResMed in Germany as a separate business segment and will serve as a platform for further developments in the field of digital health MARTINSRIED, Germany and LEIPZIG, Germany, Aug. 02, 2022 (GLOBE NEWSWIRE) --  ResMed (NYSE:RMD, ASX: RMD))) today announced the acquisition of Leipzig-based company mementor; the deal was completed Monday, August 1. With this acquisition, ResMed strengthens its overall sleep